

4. The protein of claim 1, further comprising a signal peptide polyhistidine, and a T-cell helper epitope.

Sub  
FY 5. The protein of claim 1, wherein the stages are one or more of sporozoite stage, liver stage, blood stage or sexual stage.

6. The protein of claim 5, comprising at least one antigenic epitope from each of the sporozoite, liver, blood, and sexual stages of *Plasmodium falciparum* life cycle.

D3 Sub  
FY 10. A protein composition comprising the recombinant protein of claim 1, in a pharmaceutically acceptable carrier.

#### REMARKS

Claim 3 is amended herein to make it independent by incorporating the limitations of claim 1, from which claim 3 depended. Support for this amendment can be found at least at page 3, lines 31-33 of the specification, and in claim 1. No new matter has been added by this amendment. Claims 1, 4, 5, 6, and 10 are reiterated herein.

After entry of this amendment, claims 1, 3-6 and 10 are pending in this application. Consideration of these claims is requested.

#### *Withdrawn rejections and objections:*

Applicant thanks the Examiner for withdrawing the objection to claim 10, and the rejections of claims 1-6 and 10 under 35 U.S.C. § 112, first paragraph; claims 1-3, 5, 6 and 10 under 35 U.S.C. § 102; and claims 1-3, 5, 6 and 10 under 35 U.S.C. § 102(a) (previously stated as a rejection under 35 U.S.C. § 102(b)).

#### *Claim objections:*

The Office action states that claim 10 is objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form. Applicant thanks the